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Abstract
Background: The rhizomes of Panax japonicus are used as a folk medicine for treatment of life-
style related diseases such as arteriosclerosis, hyperlipidemia, hypertension and non-insulin-
dependent diabetes mellitus as a substitute for ginseng roots in China and Japan. Obesity is closely
associated with life-style-related diseases. This study was performed to clarify whether
chikusetsusaponins prevent obesity induced in mice by a high-fat diet for 9 weeks.
Methods: We performed two in vivo experiments. In one, female ICR mice were fed a high-fat diet
with or without 1 or 3% chikusetsusaponins isolated from P. japonicus rhizomes for 9 weeks. In the
other, lipid emulsion with or without chikusetsusaponins was administered orally to male Wistar
rats, and then the plasma triacylglycerol level was measured 0.5 to 5 h after the orally administered
lipid emulsion. For in vitro experiments, the inhibitory effects of total chikusetsusaponins and
various purified chikusetsusaponins on pancreatic lipase activity were determined by measuring the
rate of release of oleic acid from triolein in an assay system using triolein emulsified with lecithin.
Results: Total chikusetsusaponins prevented the increases in body weight and parametrial adipose
tissue weight induced by a high-fat diet. Furthermore, consumption of a high-fat diet containing 1
or 3% total chikusetsusaponins significantly increased the fecal content and triacylglycerol level at
day 3 compared with the high-fat diet groups. Total chikusetsusaponins inhibited the elevation of
the plasma triacylglycerol level 2 h after the oral administration of the lipid emulsion. Total
chikusetsusaponins, chikusetsusaponin III, 28-deglucosyl-chikusetsusaponin IV and 28-deglucosyl-
chikusetsusaponin V inhibited the pancreatic lipase activity.
Conclusion: The anti-obesity effects of chikusetsusaponins isolated from P. japonicus rhizomes in
mice fed a high-fat diet may be partly mediated through delaying the intestinal absorption of dietary
fat by inhibiting pancreatic lipase activity. The present study clearly indicated that the saponin
fractions of P. japonicus rhizomes had a significant anti-obesity action and supports the traditional
usage as a substitute drug for ginseng roots.
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Background
The rhizomes of Panax japonicus C.A. Meyer (Japanese
name; Chikusetsuninjin), have been used as a substitute
for Ginseng roots (the roots of Panax ginseng C.A. Meyer).
On the other hand, Ginseng roots are used as the remedy
for life-style-related diseases such as arteriosclerosis
hyperlipidemia, hypertension and non-insulin-depend-
ent diabetes mellitus in China, Korea, Japan and Europe
and there are a number of reports on the pharmacological
studies of Ginseng roots [1-8]. It has been reported that
the rhizomes of Panax japonicus have anti-ulcer action and
fibrinolysis [9,10]. However, the investigations of phar-
macological effects of Panax japonicus rhizomes on life-
style-related diseases such as obesity, arteriosclerosis
hyperlipidemia, hypertension and non-insulin-depend-
ent diabetes mellitus have been not thoroughly reported.
Obesity is one of the fastest-growing major diseases in
many areas of the world including Europe, the United
States and Japan. Obesity results from an imbalance
between energy intake and expenditure. Obesity is closely
associated with life-style-related diseases such as hyperlip-
idemia, hypertension, arteriosclerosis and non-insulin-
dependent diabetes mellitus and with increased risk of
coronary heart disease [11]. It has been reported that var-
iations in total energy intake and diet composition are
important in the regulation of metabolic processes
[12,13]. Furthermore, it has been suggested that dietary
fat promotes body fat storage more effectively than dietary
carbohydrate. Thus, inhibition of the digestion and
absorption of dietary fat is a key to treating obesity. Die-
tary fat is not directly absorbed from the small intestine
unless it has been subjected to the action of pancreatic
lipase [14]. In this study, we examined the effects of total
chikusetsusaponins of P. japonicus rhizomes on obesity
induced by long-term feeding of a high-fat diet.
Methods
Materials
Pancreatic lipase was purchased from Sigma Chemical Co.
(St Louis, MO). Triglyceride E- and Total Cholesterol E-
test kits were purchased from Wako Pure Chemical Co.
(Osaka, Japan). Laboratory pellet chow was purchased
from CLEA Japan (Osaka, Japan). Beef tallow, casein, vita-
min and mineral mixtures were purchased from Oriental
Yeast Co. Ltd (Tokyo, Japan). Orlistat (a lipase inhibitor)
was purchased from Hong Kong Market. Other chemicals
were of reagent grade.
Plant materials
The rhizomes of P. japonicus were obtained from Tochim-
oto Tennkaido Co. Ltd. (Osaka, Japan). Voucher speci-
mens (No. PJ020817) are deposited in the Faculty of
Environmental and Symbiotic Sciences, Prefectural Uni-
versity of Kumamoto and the Second Department of Med-
ical Biochemistry, School of Medicine, Ehime University.
Preparation of total saponins and five chikusetsusaponins 
from the rhizomes of P. japonicus
Chikusetsusaponins were isolated using by a modifica-
tion of previous reported method [15,16]. The dried rhi-
zomes of P. japonicus (1 kg) were extracted three times by
refluxing with methanol (3 L). After removal of the sol-
vent from the methanol solution under reduced pressure,
the extract (370 g) was subjected to chromatography on
reversed-phase highly porous polymer [DIAION HP-20 (4
kg), Mistubishi Chemical Ind. Ltd.: elution with H2O
(800 mL), MeOH (500 mL), and CHCl3 (300 mL)] to pro-
vide the three fractions such as H2O eluate (235 g), MeOH
eluate (130 g), and CHCl3 eluate (5 g). The fraction eluted
with methanol was designated the "total chikusetsusa-
ponins". The MeOH eluate (total saponin fraction, 110 g)
was separated by column chromatography on silica gel
[silica gel G (2 kg), Merck, CHCl3-MeOH-H2O] to furnish
four fractions and the fractions 2 and 3 were purified by
HPLC (YMC-pack ODS, MeOH-H2O-AcOH) to give
chikusetsusaponins III (13.5 g), IV (6.2 g) and V (54.5 g),
28-deglucosylchikusetsusaponins IV (15 mg) and V (110
mg). 28-Deglucosylchikusetsusaponins IV and V were
also obtained by alkaline hydrolysis of chikusetsusapon-
ins IV and V, respectively. The isolated five compounds
were identified by comparison of their physical data
([α ]D, IR, 1H- and 13C-NMR) with reported values [15,16].
The purity of each compound was over 95% based on the
analysis by HPLC (Fig. 1).
Diet compositions
Previously, we reported that varying the casein concentra-
tion (22, 31, 34 and 36 % diets) in high-fat diet contain-
ing 40 % beef tallow did not affect body weight or
parametrial adipose tissue weight [17]. Therefore, we sub-
stituted 1 or 3% total chikusetsusaponins isolated from P.
japonicus rhizomes for an equivalent mass of casein in the
high-fat diets shown in Table 1. To avoid autooxidation of
the fat components, food was stored at -30°C. If the diet
except fat from high-fat diet was used as control diet, car-
bohydrate (e.g. corn starch or sugar) instead of fat was
added to the diet; and consequently this diet is high-car-
bohydrate diet. Black et al. reported that feeding high-car-
bohydrate diet containing 73% kcal corn starch for 16
weeks elevated the α -disaccharidase activity in small intes-
tine [18]. Therefore, it seems likely that the high-carbohy-
drate diet may affect carbohydrate metabolism. In this
study, we used laboratory chow diet as a control diet.
Animals
Female ICR strain mice (3 weeks old) and male Wistar
King strain rats (6 weeks old) were obtained from CLEA
Japan (Osaka, Japan) and Charles River Japan (Yoko-
hama, Japan), respectively, and housed for 1 week under
a 12 h/12 h light/dark cycle in a temperature- and humid-
ity-controlled room.BMC Complementary and Alternative Medicine 2005, 5:9 http://www.biomedcentral.com/1472-6882/5/9
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The animals were given free access to food and water. After
adaptation to the lighting conditions for 1 week, the
healthy animals were used in these experiments. The
experimental protocol was approved by the Animal Stud-
ies Committees of Ehime University and Kumamoto Pre-
fectural University.
Estimation of body and parametrial adipose tissue weights, 
plasma triacylglycerol and total cholesterol in mice fed a 
high-fat diet for 9 weeks
Female ICR mice (3 weeks old) were divided into four
groups that were matched for body weight, after 1 week of
being fed laboratory pellet chow ad libitum. The control
group continued to be fed laboratory pellet chow ad libi-
tum. The mice consumed the high-fat diet or the high-fat
diet containing 1 and 3% total chikusetsusaponins or
0.012 and 0.024% orlistat (positive control) for 9 weeks.
The body weight of each mouse was measured once a
week and the total amount food consumed was recorded
3 times per week. After the mice had been fed these diets
for 9 weeks, blood was taken from each mouse by venous
puncture under anesthesia with diethyl ether; the mice
were then killed with an overdose of diethyl ether. Exper-
iments were performed in a ventilated room. The plasma
was prepared and frozen at -80°C until analysis. The liver
and parametrial adipose tissue were dissected and
weighed. Liver triacylglycerol and total cholesterol con-
centrations were measured using Wako Triglyceride E-Test
and Total Cholesterol E-Test kits.
Fat excretion in feces of mice
Female ICR mice (3 weeks old) were housed for 1 week in
a room maintained at 25 ± 1°C with 60% relative humid-
ity and given free access to standard laboratory pellet
chow and water. The mice consumed the high-fat diet or
the high-fat diet containing 1% or 3% total chikusetsusa-
ponins, or 0.025% orlistat for 3 days. Wet weight and tri-
acylglycerol content in the feces obtained during the last
24 h were measured using the Wako Triglyceride E-Test
kit.
Plasma triacylglycerol levels after oral administration of 
lipid emulsions to rats
Male Wistar rats were also housed for 1 week in the above
same conditions. After rats had been deprived of food
overnight, they were orally administered 1 mL of a lipid
emulsion consisting of corn oil (3 mL), cholic acid (40
mg) and cholesteryl oleate (1 g) plus physiological saline
(3 mL), the lipid emulsion (1 mL) plus total chikusetsusa-
ponins (final concentration 1000 mg/kg body) or the
lipid emulsion plus orlistat (final concentration 45 mg/kg
body). Blood samples were taken from the tail vein 0, 0.5,
1, 2, 3, 4 and 5 h after administration of the lipid emul-
sion with or without total saponins or orlistat using a cap-
illary tube (heparinized), and centrifuged at 5500 × g for
5 min in a Model KH-120 M (Kubota Co., Osaka, Japan)
centrifuge to obtain the plasma. The plasma triacylglyc-
erol concentration was determined using a Wako Triglyc-
eride E-Test kit.
In vitro pancreatic lipase activity
Lipase activity in the porcine pancreas was assay as
described previously [19]. Enzyme activity was expressed
as µmoles of oleic acid released per mL of reaction mixture
per min.
The structure of various chikusetsusaponins Figure 1
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Statistical analysis
All values are expressed as means ± s.e. Data were ana-
lyzed by one-way ANOVA, and then differences among
means were analyzed using the Fisher's protected LSD test.
Differences were considered significant at P < 0.05.
Results
Fat excretion in feces of mice fed a high-fat diet with or 
without total chikusetsusaponins
Consumption of the high fat diet for 3 days reduced the
feces weight (0.14 ± 0.035 g/mouse/day) at day 3 com-
pared with that of the control group (1.04 ± 0.017 g /
mouse/day). Mice fed the high-fat diet plus 3% total
chikusetsusaponins, or 0.025% orlistat for 3 days had sig-
nificantly higher triacylglycerol level at day 3 compared
with the high-fat diet group (Table 2).
Food consumption; body, parametrial adipose tissue and 
liver weights; and triacylglycerol content in the livers of 
mice fed high-fat diet with or without chikusetsusaponins 
for 9 weeks
The mean food consumption per week per mouse was sig-
nificantly different between the control group and high-
fat diet groups, being 409.4 ±7.0 KJ in the control group
and 611.0 ± 41.6 KJ in the high-fat diet group?? but was
not significantly different among the high-fat diet groups,
high-fat plus 1% and 3% saponin-diet groups, and high-
fat plus 0.012% orlistat-diet groups, being 611.0 ± 41.6 KJ
(high-fat diet), 708.7 ± 34.6 KJ (high-fat diet plus 1%
chikusetsusaponin), 686.0 ± 30.0 KJ (high-fat diet plus
3% chikusetsusaponin) and 693.1 ± 53.8 KJ (high-fat diet
plus 0.012% orlistat). A high-fat plus 0.024% orlistat diet
significantly reduced the body weight to 4 weeks com-
pared to both the normal and the high-fat diet groups, but
among 15 mice of high-fat plus 0.024% orlistat-diet
groups, 10 mice died by the severe diarrhea until 5 weeks
by the feeding high-fat diet containing 0.024% orlistat
(data not shown). Orlistat is a potent inhibitor of pancre-
atic lipase; therefore, the absorption of dietary fat from
small intestine was strongly inhibited by feeding high-fat
diet containing 0.025% orlistat (Table 2). Mice treated
with high-fat diet plus 0.024% orlistat for a long term died
by severe diarrhea, but high-fat diet plus 0.012% orlistat-
fed mice did not cause diarrhea (data not shown). This
finding suggests that feeding level of 0.024% orlistat in
the high-fat diet to mice for a long term may cause the
Table 1: Composition of experimental high-fat diets
Total chikusetsusaponins (g/100 g diet)
High-fat diet (HF) HF + 1% 
chikusetusaponins
HF + 3% 
chikusetsusaponins
HF + 0.012% orlistat HF + 0.024% orlistat
Beef tallow 40 40 40 40 40
Corn starch 10 10 10 10 10
S u g a r 99999
M i n e r a l  m i x t u r e 44444
V i t a m i n  m i x t u r e 11111
Casein 36 35 33 36 36
T o t a l  s a p o n i n s 01300
Orlistat 0 0 0 0.012 0.024
Table 2: Effects of total chikusetsusaponins and orlistat (a lipase inhibitor) on fat excretion on day 3 in feces of mice fed a high-fat diet
Animal No. Feces weight (g) Triacyglycrol in feces (µmol/g feces)
Laboratory chow pellet 13 1.04 ± 0.017* 5.05 ± 0.70*
High-fat diet (HF) 13 0.14 ± 0.035 36.66 ± 1.03
HF +
1% Total chikusetsusaponins 7 0.26 ± 0.012* 41.64 ± 3.48
HF +
3% Total chikusetsusaponins 7 0.31 ± 0.049 53.42 ± 4.86*
HF +
0.025 % orlistat (lipase inhibitor) 7 0.22 ± 0.040 394.38 ± 65.39*
Values are means ± S.E. of 7 – 13 mice. * Significantly different from the high-fat diet group, P < 0.05.BMC Complementary and Alternative Medicine 2005, 5:9 http://www.biomedcentral.com/1472-6882/5/9
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physiological toxicity through the continuous inhibition
of pancreatic lipase. Feeding high-fat plus 0.012% orlistat
diet had no effect on the adipose tissue weight. In the
present study, the discrepancy between anti-obesity action
and inhibitory action of pancreatic lipase by orlistat could
not sufficiently be clarified; therefore, this discrepancy is
needed to clarify in future studies. Figure 2 shows the
changes in body weight of the groups during the experi-
ment. Consuming a high-fat diet for 9 weeks caused sig-
nificant increases in body weight at 1 to 9 weeks
compared to that of the control group (laboratory pellet
chow). Consuming a high-fat diet supplemented with 1%
or 3% chikusetsusaponins significantly suppressed the
increase in body weight during the experimental period
compared to the high-fat diet, but the high-fat diet plus
0.012% orlistat did not affect. The final parametrial adi-
pose tissue weights of the groups are shown in Table 3.
The final parametrial adipose tissue weight was signifi-
cantly increased by consumption of a high-fat diet com-
pared to the control diet, and that in animals with a high-
fat diet containing 1% or 3% chikusetsusaponins was sig-
nificantly reduced as compared to that in the high-fat diet
group. Furthermore, mice fed a high-fat diet long term
developed fatty liver, with increases of the liver weight and
an accumulation of hepatic triacylyglycerol compared to
the control group. Consumption of a high-fat diet con-
taining 1% or 3% chikusetsusaponins, or 0.012% orlistat
reduced the liver weight and hepatic triacylglycerol con-
tent compared to consumption of a high-fat diet group
(Table 3).
Total chikusetsusaponins reduced the elevation of rat 
plasma triacylglycerol levels after oral administration of 
lipid emulsion to rats
The plasma triacylglycerol level (2.98 ± 0.31 mM, n = 4)
at 2 h after orally administered lipid-emulsion was
significantly reduced to 1.66 ± 0.28 mM (n = 4) and 0.93
± 0.16 mM (n = 4), respectively, by the oral administra-
tion of total chikusetsusaponins (1000 mg/kg) and orli-
stat (45 mg/kg) (Fig. 3).
Effects of total chikusetsusaponins and various purified 
chikusetsusaponins on pancreatic lipase activity in vitro
As shown in Fig. 4a, methanol extracts, total chikusetsusa-
ponins and the positive control orlistat dose dependently
inhibited pancreatic lipase activity in an assay system
using triolein emulsified with lecithin, but water and
CHClS3-eluate fraction had no effect. We then examined
the various chikusetsusaponins isolated from P. japonicus
rhizomes. Chikusetsusaponin III and 28-deglucosylchiku-
setsusaponins IV and V dose-dependently inhibited the
pancreatic lipase activity at concentrations of 125 to 500
µg/mL (Fig. 4b).
Discussion
There are a number of reports showing that ginseng roots
are clinically anti-allergic, anti-hypertensive, hypoglyc-
emic, anti-thrombotic, and anti-arteriosclerotic [7,8].
Recently, obesity is increasing in advanced countries
including Europe, the United States and Japan. Obesity is
closely associated with life-style-related diseases such as
hyperlipidemia, hypertension, arteriosclerosis and non-
insulin-dependent diabetes mellitus and with increased
risk of coronary heart disease [11]. Although the rhizomes
of P. japonicus are used as a substitute drug for ginseng
roots in Japan, the pharmacological effects of these rhi-
zomes on life-style-related diseases have been not clari-
fied. A methanol extract of these rhizomes and
chikusetsusaponins such as chikusetsusaponins III, IV and
V derived from P. japonicus rhizomes have been shown to
promote the fibrinolysis [10]. Yamahara et al. [9] reported
that the saponin fractions and chikusetsusaponin III of P.
japonicus exert anti-ulcer effects. However, there have hith-
erto been no reports on the inhibitory effects of chikuset-
susaponins isolated from P. japonicus rhizomes on obesity
induced by consumption of a high-fat diet. Dietary fat can
increase body weight and adiposity in humans and ani-
Table 3: Effects of total chikusetsusaponins and orlistat (a lipase inhibitor) on liver weight, hepatic triacylglycerol, and adipose tissue 
weight in mice fed a high-fat diet for 9 weeks.
Animal No. Liver weight (g/100 g body 
weight)
Hepatic triacylglycerol (µmol/g) Parametrial adipose tissue 
weight (g)
Laboratory chow pellet 26 5.20 ± 0.46* 22.3 ± 2.3* 0.71 ± 0.1*
High-fat diet (HF) 26 6.35 ± 0.76 141.8 ± 21.8 1.59 ± 0.3
HF +
1% Total saponins 11 6.13 ± 0.79 101.5 ± 6.8* 0.87 ± 0.1*
HF +
3% Total saponin 11 5.79 ± 0.47* 83.3 ± 6.7* 0.74 ± 0.1*
HF + 0.012% Orlistat 15 4.00 ± 0.11* 101.1 ± 4.8* 2.03 ± 0.12
Values are means ± S.E. of 11 – 26 mice. *Significantly different from the high-fat diet group, P < 0.05.BMC Complementary and Alternative Medicine 2005, 5:9 http://www.biomedcentral.com/1472-6882/5/9
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Effects of chikusetsusaponins and orlistat (a lipase inhibitor) on body weight in mice fed a high-fat diet for 9 weeks Figure 2
Effects of chikusetsusaponins and orlistat (a lipase inhibitor) on body weight in mice fed a high-fat diet for 9 
weeks. Open circles, normal groups; solid circles, high-fat diet groups; open squares, high-fat plus 1% total chikusetsusaponin 
diet groups; solid squares, high-fat plus 3% total chikusetsusaponin diet groups; solid triangle, high-fat plus 0.012% orlistat diet. 
Values are means ± S.E. of 11–26 mice. * Significantly different from the high-fat diet group, P < 0.05.
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Effects of total chikusetsusaponins and orlistat (a lipase inhibitor) on rat plasma triacylglycerol levels after oral administration of  a lipid emulsion Figure 3
Effects of total chikusetsusaponins and orlistat (a lipase inhibitor) on rat plasma triacylglycerol levels after oral 
administration of a lipid emulsion. Open circles, lipid emulsion; solid circles, lipid emulsion plus total chikusetsusaponins 
(1000 mg/kg) and open squares, lipid emulsion plus orlistat (a lipase inhibitor) (45 mg/kg). Values are means ± S.E. of 4 rats. * 
Significantly different from lipid-emulsion-only treated group, P < 0.05.
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Effects of total chikusetsusaponins, various chikusetsusaponins and orlistat (a lipase inhibitor) on pancreatic lipase activity Figure 4
Effects of total chikusetsusaponins, various chikusetsusaponins and orlistat (a lipase inhibitor) on pancreatic 
lipase activity. Values are means ± S.E. of 4 experiments. a) Solid circles, methanol extract; open circles, total chikusetsusa-
ponins; open squares, orlistat (a lipase inhibitor) was used as a positive control. b) Open circles, chikusetsusaponin III; solid cir-
cles, chikusetsusaponin IV; open squares, 28-deglucosyl-chikusetsusaponin IV; solid squares, 28-deglucosyl-chikusetsusaponin V.
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mals more effectively than dietary carbohydrate [17,20-
22]. Dietary fat is not directly absorbed from the intestine
unless it has been subjected to the action of pancreatic
lipase [14]. Therefore, the application of pancreatic lipase
inhibitor was examined earlier as a treatment for high-fat
diet-induced obesity in humans. It has been reported that
a pancreatic lipase inhibitor, orlistat prevented obesity
and hyperlipidemia through the enhancement of fat
excretion in feces and the inhibition of pancreatic lipase
[23]. We found that feeding high-fat diet containing 40%
fat content caused obesity [17,19], but the high-fat diet
containing 25% fat content slightly increased the body
weight (data not shown). Anai et al. reported that feeding
high-fat diet containing 60% fat for 2 weeks slightly
increased the body weight [24]. Furthermore, it has been
reported that feeding high-fat diet containing 58% kcal fat
for 16 weeks caused obesity [18]. In the present study, to
examine the effects of chikusetsusaponins on high-fat
diet-induced obesity, we used the obesity model induced
by feeding high-fat diet containing 40% fat for 9 weeks.
We found that the administration of total chikusetsusa-
ponins isolated from P. japonicus significantly suppressed
the increase in body weight in mice fed a high-fat diet con-
taining 40% beef tallow for 9 weeks. The treatment with
total chikusetsusaponins also significantly reduced the
final parametrial adipose tissue weight compared to that
of the high-fat diet group. These inhibitions did not
depend on decreased food or energy intake, because there
was no significant difference between these in the groups
fed the high-fat diet and the high-fat diet containing 1 or
3 % total chikusetsusaponin. Next, we examined the
effects of total chikusetsusaponins on plasma triacylglyc-
erol concentrations after oral administration of a lipid
emulsion in rats, and found that the total chikusetsusa-
ponins reduced the elevation of plasma triacylglycerol lev-
els as measured by an oral lipid emulsion tolerance test.
This finding suggests that total chikusetsusaponins may
inhibit the uptake of dietary fat. In fact, total chikusetsu-
saponins strongly inhibited the pancreatic lipase activity,
and therefore, we attempted to isolate substance(s) from
total saponins that inhibit pancreatic lipase activity. Five
chikusetsusaponins were isolated from total saponin frac-
tions and identified as chikusetsusaponins III, IV and V
and 28-deglucosyl-chikusetsusaponins IV and IV by the
direct comparison with authentic samples. Among these
five saponins, chikusetsusaponin III and 28-degluco-
sylchikusetsusaponins IV and V inhibited the pancreatic
lipase activity, most strongly. The contents of total chiku-
setsusaponins in the MeOH extract are about 35%, and
the contents of chikusetsusaponins III, IV and V in the
total saponin fraction are about 10.4, 4.8 and 41.9%,
respectively. On the other hand, the content of 28-deglu-
cosylchikusetsusaponins IV and V in the total saponins
are about 0.01 and 0.08%, respectively. Chikusetsusapon-
ins IV and V are rapidly converted to 28-deglycosyl-forms
by the treatment with alkaline solution. Therefore, it
seems likely that the above 28-deglucosylchikusetsusa-
ponin derive from chikusetsusaponins IV and V through
the small intestine after orally administered chikusetsusa-
ponins IV and V. Consequently, it is suggested that their
metabolites (28-deglucosyl form) exhibit the inhibition
of pancreatic lipase activity.
Conclusion
Total chikusetsusaponins isolated from P. japonicus may
prevent high-fat-diet-induced increases in body weight
and fat storage in adipose tissue by inhibiting intestinal
absorption of dietary fat through the inhibition of pancre-
atic lipase activity, and the active components were iden-
tified here as chikusetsusaponins III and IV, 28-
deglucosyl-chikusetsusaponins IV and V. The present
study clearly indicated that the saponin fractions of P.
japonicus rhizomes had a significant anti-obesity action
and supports the traditional usage as a substitute drug for
ginseng roots. Hence it might help in preventing obesity
complications and serve as good adjuvant in the present
armamentarium of anti-obesity drugs.
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